Company news
AN2 Therapeutics, Inc. news in 2023
AN2 Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 8, 2023
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
October 17, 2023
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
September 25, 2023
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
September 12, 2023
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
August 14, 2023
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 9, 2023
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 10, 2023
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 28, 2023